Korro presents additional preclinical data for krro-110 at the american thoracic society 2024 international conference

Cambridge, mass., may 20, 2024 (globe newswire) --  korro bio, inc. (korro) (nasdaq: krro), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for krro-110, its development candidate for the treatment of aatd.
KRRO Ratings Summary
KRRO Quant Ranking